Age-related macular degeneration 2

Common Name(s)

Age-related macular degeneration 2

Description for this condition is not yet available.
 

Advocacy and Support Organizations

 

Condition Specific Organizations

Following organizations serve the condition "Age-related macular degeneration 2" for support, advocacy or research.

There are currently no organizations listed in Disease InfoSearch that support this condition. Create a listing.

 

 

General Support Organizations

Not finding the support you need? Show General Support Organizations

 
 
Top

How do you compare to others with this condition?

Privately answer questions about your health. Let resources, you select, come to you.

Anonymously share and see how your answers compare with others with this condition while privately providing key pieces of information to medical researchers, disease advocacy groups, and others ONLY YOU select to help speed up cures and better alternatives.

 
 

Advocacy and Support Organizations

 

Condition Specific Organizations

Following organizations serve the condition "Age-related macular degeneration 2" for support, advocacy or research.

There are currently no organizations listed in Disease InfoSearch that support this condition. Create a listing.

 

 

General Support Organizations

Not finding the support you need? Show General Support Organizations

 
 
 
 
Top

Scientific Literature

Articles from the PubMed Database

Research articles describe the outcome of a single study. They are the published results of original research.
The terms "Age-related macular degeneration 2" returned 26 free, full-text research articles on human participants. First 3 results:

Efficacy and safety of intravitreal aflibercept injection in wet age-related macular degeneration: outcomes in the Japanese subgroup of the VIEW 2 study.
 

Author(s): Yuichiro Ogura, Hiroko Terasaki, Fumi Gomi, Mitsuko Yuzawa, Tomohiro Iida, Miki Honda, Koichi Nishijo, Olaf Sowade, Tetsushi Komori, Ursula Schmidt-Erfurth, Christian Simader, Victor Chong,

Journal: Br J Ophthalmol. 2015 Jan;99(1):92-7.

 

To evaluate efficacy and safety of intravitreal aflibercept (IVT-AFL) in Japanese patients with wet age-related macular degeneration (wAMD) from the VIEW 2 trial.

Last Updated: 16 Dec 2014

Go To URL
Cost-effectiveness of ranibizumab and bevacizumab for age-related macular degeneration: 2-year findings from the IVAN randomised trial.
 

Author(s): Helen A Dakin, Sarah Wordsworth, Chris A Rogers, Giselle Abangma, James Raftery, Simon P Harding, Andrew J Lotery, Susan M Downes, Usha Chakravarthy, Barnaby C Reeves,

Journal:

 

To assess the incremental cost and cost-effectiveness of continuous and discontinuous regimens of bevacizumab (Avastin) and ranibizumab (Lucentis) for neovascular age-related macular degeneration (nAMD) from a UK National Health Service (NHS) perspective.

Last Updated: 1 Aug 2014

Go To URL
Twenty-four-month efficacy and safety of 0.5 mg or 2.0 mg ranibizumab in patients with subfoveal neovascular age-related macular degeneration.
 

Author(s): Allen C Ho, Brandon G Busbee, Carl D Regillo, Mark R Wieland, Sherri A Van Everen, Zhengrong Li, Roman G Rubio, Phillip Lai,

Journal: Ophthalmology. 2014 Nov;121(11):2181-92.

 

To evaluate the 24-month efficacy and safety of intravitreal ranibizumab 0.5 mg and 2.0 mg administered monthly or as needed (pro re nata [PRN]) in patients with neovascular age-related macular degeneration (wet AMD).

Last Updated: 2 Dec 2014

Go To URL

Reviews from the PubMed Database

Review articles summarize what is currently known about a disease. They discuss research previously published by others.
The terms "Age-related macular degeneration 2" returned 1 free, full-text review articles on human participants. First 3 results:

The association between complement component 2/complement factor B polymorphisms and age-related macular degeneration: a HuGE review and meta-analysis.
 

Author(s): Ammarin Thakkinstian, Mark McEvoy, Usha Chakravarthy, Subhabrata Chakrabarti, Gareth J McKay, Euijung Ryu, Giuliana Silvestri, Inderjeet Kaur, Peter Francis, Takeshi Iwata, Masakazu Akahori, Astrid Arning, Albert O Edwards, Johanna M Seddon, John Attia

Journal: Am. J. Epidemiol.. 2012 Sep;176(5):361-72.

 

The authors performed a systematic review of the association of complement component 2(C2)/complement factor B (CFB) gene polymorphisms with age-related macular degeneration (AMD). In total, data from 19 studies published between 2006 and 2011 were pooled for 4 polymorphisms: rs9332739 ...

Last Updated: 29 Aug 2012

Go To URL
 
 
Top

Symptoms, Diagnosis, and Treatment

There are currently no related results available in GeneReviews.

 
 
Top

Clinical Trial Information This information is provided by ClinicalTrials.gov

Safety and Tolerability of Ranibizumab in Mono/Bilateral w-AMD Patients in Eyes With BCVA<2/10 and/or 2nd Affected Eye
 

Status: Recruiting

Condition Summary: Wet Age Related Macular Degeneration

 

Last Updated: 9 Dec 2014

Go to URL
Efficacy and Safety of RTH258 Versus Aflibercept - Study 2
 

Status: Not yet recruiting

Condition Summary: Neovascular Age-Related Macular Degeneration

 

Last Updated: 30 Apr 2015

Go to URL